The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study-Reference-Cited by-同舟云学术

The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study

Published:2011-02-21 Issue:3 Volume:17 Page:412-421
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:

Author:

KLAMROTH R.,POLLMANN H.,HERMANS C.,FARADJI A.,YARLAS A. S.,EPSTEIN J. D,EWENSTEIN B. M

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2516.2010.02435.x/fullpdf

Reference31 articles.

1. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV;Darby;Blood,2007

2. Changes in the life expectancy of patients with severe haemophilia A in Finland in 1930-79;Ikkala;Br J Haematol,1982

3. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study;Plug;J Thromb Haemost,2006

4. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group;Aledort;J Intern Med,1994

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study;Therapeutic Advances in Hematology;2024-01

3. Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults;Research and Practice in Thrombosis and Haemostasis;2023-08

4. Effectiveness of therapeutic exercise and cognitive‐behavioural therapy combined protocol on functionality, pain and joint health in people with haemophilia: Secondary analysis of a controlled trial;Haemophilia;2022-12-26